Eli Lilly has launched Foundayo (orforglipron), a once-daily oral medicine, in the UK for weight management and type 2 diabetes. The Foundayo UK launch makes the country the first in Europe where the medicine is commercially available, following UK regulatory authorisation on 10 August 2026.
Foundayo is currently available through private prescription, while its potential availability through the UK’s National Health Service (NHS) is being assessed.
Quick Summary
Foundayo (orforglipron) is Eli Lilly’s once-daily oral GLP-1 receptor agonist launched in the UK in 2026. It is authorised for weight management and certain adults with inadequately controlled type 2 diabetes. The expected private price is £100–£120 per month, while NHS availability remains under assessment.
Foundayo UK: Key Highlights
| Particular | Details |
|---|---|
| Brand Name | Foundayo |
| Active Ingredient | Orforglipron |
| Manufacturer | Eli Lilly |
| Dosage Form | Oral tablet |
| Administration | Once daily |
| Uses | Weight management and type 2 diabetes |
| UK Regulatory Authorisation | 10 August 2026 |
| UK Availability | Private prescription |
| Expected UK Price | £100–£120 per month |
| Mounjaro Monthly Price Mentioned | About £330 |
| NHS Availability | Under assessment |
What Is Foundayo?
Foundayo is an oral medicine containing orforglipron, a GLP-1 receptor agonist developed by Eli Lilly.
It is designed for weight management in eligible adults and is intended to be used alongside a reduced-calorie diet and increased physical activity.
The medicine is also authorised for adults with inadequately controlled type 2 diabetes, according to the information provided in the source material.
Is Foundayo a Tablet or Injection?
Foundayo is an oral tablet taken once daily. This differentiates it from injectable GLP-1 medicines such as Mounjaro.
One of the highlighted convenience features of Foundayo is that it can be taken without the food and water restrictions associated with the oral Wegovy treatment described in the source material.
Foundayo UK Launch 2026
Eli Lilly launched Foundayo in the UK following regulatory authorisation on 10 August 2026.
According to the provided information, the UK is the first European country where Foundayo is commercially available.
For now, patients can access the medicine through private providers with a prescription.
NHS access is a separate process because the medicine still needs to undergo the relevant health technology and cost-effectiveness assessment.
Foundayo Price in the UK
The expected private price of Foundayo in the UK is £100–£120 per month.
This is lower than the approximately £330 monthly price mentioned for Mounjaro through private providers.
| Medicine | UK Monthly Price Mentioned |
|---|---|
| Foundayo | £100–£120 expected |
| Mounjaro | About £330 |
| Wegovy pill | About £74–£129 for initial low doses |
Prices may vary depending on the provider, dosage and treatment plan.
How Does Foundayo Work?
Foundayo contains orforglipron, which belongs to the GLP-1 receptor agonist class.
GLP-1-based medicines are used to influence appetite and blood glucose regulation.
For weight management, Foundayo is intended to be used along with a reduced-calorie diet and increased physical activity.
For type 2 diabetes, it is authorised for eligible adults whose condition is inadequately controlled.
Foundayo vs Mounjaro
Foundayo and Mounjaro are both associated with Eli Lilly, but they contain different active ingredients and are administered differently.
| Feature | Foundayo | Mounjaro |
|---|---|---|
| Active Ingredient | Orforglipron | Tirzepatide |
| Dosage Form | Oral tablet | Injection |
| Administration | Once daily | Injection |
| UK Price Mentioned | £100–£120/month expected | About £330/month |
| UK Access | Private prescription | Available through private providers |
The major convenience difference is the oral, once-daily format of Foundayo, which may appeal to people who prefer tablets rather than injections.
Foundayo vs Wegovy Pill
Foundayo and oral Wegovy are both oral GLP-1-based treatments, but their administration instructions differ.
Foundayo
Foundayo can be taken once daily without the food and water restrictions described for the oral Wegovy treatment.
Wegovy Pill
The oral Wegovy treatment requires specific fasting conditions, including taking the medicine with a small amount of water and waiting before consuming food, beverages or other medicines.
Therefore, administration convenience may be an important consideration for eligible patients and healthcare professionals.
Who Can Access Foundayo?
Foundayo is a prescription-only medicine.
Based on the information provided, it is intended for:
- Adults with obesity.
- Certain adults who are overweight and have weight-related health conditions.
- Adults with inadequately controlled type 2 diabetes under the authorised indications.
Patients should use Foundayo only under the supervision of an appropriate healthcare professional.
Foundayo Side Effects
The common side effects mentioned in the provided information include:
- Nausea
- Constipation
- Diarrhea
- Vomiting
- Indigestion
- Abdominal pain
Patients should discuss potential risks, contraindications and other medicines with a healthcare professional before starting treatment.
Important: This article is for educational and informational purposes. Foundayo is a prescription medicine and should be used only under appropriate medical supervision.
Is Foundayo Available Through the NHS?
Foundayo is not yet available through the NHS based on the information provided.
Its potential NHS availability in England is being assessed by NICE, which is evaluating whether the medicine should be recommended for NHS use.
Until that assessment is completed, patients can access Foundayo through private providers with a prescription.
The exact NHS availability date is not mentioned in the provided information.
Foundayo and NHS Assessment
Regulatory authorisation and NHS availability are two different processes.
A medicine can receive regulatory authorisation and still require a separate assessment before it becomes routinely available through the NHS.
According to the provided information, NICE is assessing Foundayo’s cost-effectiveness for potential NHS use in England.
No confirmed date for the completion of the assessment is provided in the source material.
Why Is the Foundayo Launch Important?
The Foundayo UK launch is significant because it adds another oral option to the growing GLP-1 medicine market.
Weight-management treatments have traditionally included injectable medicines. Oral GLP-1 treatments provide another administration option for eligible patients.
The launch also increases competition between major pharmaceutical companies developing oral alternatives to established injectable obesity treatments.
Foundayo vs Mounjaro vs Wegovy: Quick Comparison
| Feature | Foundayo | Mounjaro | Oral Wegovy |
|---|---|---|---|
| Company | Eli Lilly | Eli Lilly | Novo Nordisk |
| Active Ingredient | Orforglipron | Tirzepatide | Not specified in provided source |
| Form | Oral tablet | Injection | Oral tablet |
| Administration | Once daily | Injection | Specific fasting instructions |
| UK Status | Launched | Available | Available |
| Foundayo Price Mentioned | £100–£120/month expected | About £330/month | £74–£129 for initial low doses |
Prices and availability can vary by provider, dose and treatment plan.
Why Should Pharmacy Candidates Know About Foundayo?
For B.Pharm, D.Pharm, M.Pharm and pharmacy exam aspirants, Foundayo is a relevant example of the growing use of oral GLP-1 receptor agonists in weight management and type 2 diabetes.
Important points to remember include:
- Brand: Foundayo
- Active ingredient: Orforglipron
- Class: GLP-1 receptor agonist
- Dosage form: Oral tablet
- Administration: Once daily
- Manufacturer: Eli Lilly
- UK launch: 2026
- UK regulatory authorisation: 10 August 2026
These facts may also be useful for pharmacy-related current affairs and pharmaceutical industry updates.
Important Facts About Foundayo
| Question | Answer |
|---|---|
| What is Foundayo? | An oral medicine containing orforglipron |
| Who manufactures Foundayo? | Eli Lilly |
| What is orforglipron? | A GLP-1 receptor agonist |
| Is Foundayo a tablet? | Yes |
| How often is it taken? | Once daily |
| What is Foundayo used for? | Weight management and type 2 diabetes |
| When was it authorised in the UK? | 10 August 2026 |
| Is it available through the NHS? | Under assessment |
| Expected private price? | £100–£120 per month |
| Is it prescription-only? | Yes |
Frequently Asked Questions
1. What is Foundayo?
Foundayo is Eli Lilly’s once-daily oral medicine containing orforglipron, a GLP-1 receptor agonist used for authorised weight-management and type 2 diabetes indications.
2. What is the active ingredient in Foundayo?
The active ingredient in Foundayo is orforglipron.
3. Is Foundayo available in the UK?
Yes. Foundayo has launched in the UK and is currently available through private prescription according to the provided information.
4. How much does Foundayo cost in the UK?
The expected private price of Foundayo is approximately £100–£120 per month.
5. Is Foundayo cheaper than Mounjaro?
Based on the prices provided, Foundayo’s expected price of £100–£120 per month is lower than the approximately £330 monthly price mentioned for Mounjaro.
6. Is Foundayo available through the NHS?
NHS availability is currently under assessment. The provided information does not give a confirmed date for NHS availability.
7. Is Foundayo a tablet or injection?
Foundayo is an oral tablet taken once daily.
8. Is Foundayo available without a prescription?
No. Foundayo is a prescription-only medicine and should be obtained through an appropriate healthcare professional and registered pharmacy.
Conclusion
Foundayo (orforglipron) is Eli Lilly’s once-daily oral GLP-1 medicine launched in the UK in 2026 for authorised weight-management and type 2 diabetes indications.
The expected private price is £100–£120 per month, which is below the approximately £330 monthly price mentioned for Mounjaro in the provided information.
Foundayo’s UK launch provides eligible patients with another oral treatment option alongside existing injectable and oral medicines. However, NHS availability remains under assessment, and no confirmed NHS access date is mentioned in the source material.
Recommended Products
